Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California
blank

 

Recent News and Articles on the Keywords: safe and + effective therapy + therapy  Related to the article below (Last Update: 5/5/2008)

Endoscopic Pituitary Surgery Effective and Safe as the Primary ...
DG News -
... 2008 -- Surgery carried out by an endoscopic endonasal approach to the sella is well tolerated and remains the first-line therapy for cure of patients ...
Potential Viral Therapy Weapon For Difficult Cancers Is Safe And ...
Science Daily (press release) - Apr 22, 2008
"Just as important is the fact that the combination of rRp450 and CPA appears to be well tolerated, because non-cancer bearing mice treated with the therapy ...
Essentials Of Orthopaedic Nurse Care
Medical News Today (press release), UK -
Massage therapy has been shown to be safe and effective for orthopaedic patients with low back problems and potentially beneficial for patients with other ...
Divigel(R) (estradiol gel) 0.1 Percent Offers Lowest Approved Dose ...
Earthtimes (press release), UK -
Guidelines from the North American Menopause Society (NAMS) indicate that estrogen hormone therapy should be used at the lowest effective dose for the ...
High-fat, low-carb diet helps kids with epilepsy
Reuters -
This study confirms that a ketogenic diet is safe and effective in children with drug-resistant epilepsy, the investigators conclude. ...
BioElectronics Corporation Receives Major Orders From Italian ...
PR Newswire (press release), NY -
We believe health consumers with pain and soft tissue injuries will continue to view our proven, state-of-the-art ActiPatch therapy as an effective ...
Ipsen: Adenuric(R) (Febuxostat) Receives Marketing Authorisation ...
WELT ONLINE, Germany -
The availability of a new effective therapy that allows the therapeutic target to be achieved will improve the physicians armamentarium and ultimately ...TYO:3401
Thick blood
Malaysia Star, Malaysia - May 3, 2008
The options of treatment include oral therapy with hydroxyurea, anagrelide or busulphan while interferon is an effective injection therapy. ...
Amgen to Participate in Dermatologic and Ophthalmic Drugs Advisory ...
WELT ONLINE, Germany - May 1, 2008
If approved by the FDA, ENBREL would be the first biologic or systemic therapy indicated to treat this disease in pediatric patients," said Roger M. ...AMGN
Event Brief of Q1 2008 Amylin Pharmaceuticals, Inc. Earnings ...
Insurance News Net (press release), PA -
Believes this product candidate has a promise to meet the unmet medical need for a highly-effective and safe weight loss therapy. 6. ...AMLN
Source: Google News

Who would have thought it? An operation proves to be the most effective therapy for adult-onset … -
WJ Pories, MS Swanson, KG MacDonald, SB Long, PG … - Annals of Surgery, 1995 - pubmedcentral.nih.gov
... infertility. Gastric bypass is now established as an effective and safe therapy
for morbid obesity and its associated morbidities. No ...

… of psoriasis. Oral or topical use of 1, 25-dihydroxyvitamin D3 can be a safe and effective therapy … -
EL Smith, SH Pincus, L Donovan, MF Holick - J Am Acad Dermatol, 1988 - ncbi.nlm.nih.gov
... Oral or topical use of 1,25-dihydroxyvitamin D3 can be a safe and effective therapy
for psoriasis. Smith EL, Pincus SH, Donovan L, Holick MF. ...

Bronchoscopic Volume Reduction A Safe and Effective Alternative to Surgical Therapy for Emphysema -
EP INGENITO, JJ REILLY, SJ MENTZER, SJ SWANSON, … - American Journal of Respiratory and Critical Care Medicine, 2001 - Am Thoracic Soc
... Crit. Care Med., Volume 164, Number 2, July 2001, 295-301 Bronchoscopic Volume
Reduction A Safe and Effective Alternative to Surgical Therapy for Emphysema. ...

Home intravenous antibiotic therapy. A safe and effective alternative to inpatient care. -
ML Grayson, J Silvers, J Turnidge - Med J Aust, 1995 - ncbi.nlm.nih.gov
... 107 patients annually. CONCLUSIONS: Home intravenous antibiotic therapy is
safe, effective and well tolerated. It allows more efficient ...

Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome -
J Uriz? - Journal of Hepatology, 2000 - ccforum.com
... Paper Report Terlipressin plus albumin infusion: an effective and safe therapy
of hepatorenal syndrome. J Uriz, P Gines, A Cardenas ...
-

… IIb/IIIa Inhibition With Abciximab During Carotid Stenting A Safe and Effective Adjunctive Therapy -
SR Kapadia, CT Bajzer, KM Ziada, DL Bhatt, OM … - Stroke, 2001 - Am Heart Assoc
... Initial Experience of Platelet Glycoprotein IIb/IIIa Inhibition With Abciximab During
Carotid Stenting. A Safe and Effective Adjunctive Therapy. ...

… a mixed endothelin receptor antagonist in portopulmonary hypertension: A safe and effective therapy … -
C Kuntzen, V G?lberg, AL Gerbes - Gastroenterology, 2005 - Elsevier
... Case reports. Use of a mixed endothelin receptor antagonist in portopulmonary
hypertension: A safe and effective therapy? Christian ...

Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with … -
K Folkers, S Vadhanavikit, SA Mortensen - Proceedings of the National Academy of Sciences of the …, 1985 - JSTOR
... two. They concluded that CoQ10o is a safe and effective therapy for chronic
myocardial disease. Subsequently, Mortensen et al. (2 ...

Thrombolytic therapy for pulmonary embolism: Is it effective? Is it safe? When is it indicated?
JE DALEN, JS ALPERT, J HIRSH - Archives of internal medicine(1960), 1997 - cat.inist.fr
Thrombolytic therapy for pulmonary embolism: Is it effective? Is it safe?
When is it indicated? JE DALEN, JS ALPERT, J HIRSH Archives ...

A Novel Three-Pronged Approach to Kill Cancer Cells Selectively: Concomitant Viral, Double Suicide … -
SO Freytag, KR Rogulski, DL Paielli, JD Gilbert, … - Human Gene Therapy, 1998 - liebertonline.com
... We propose that the three-pronged approach of viral therapy, suicide gene therapy,
and radiotherapy may ultimately prove to be a safe and effective means of ...

Source: Google Scholar

Potentially Safe and Effective Therapy Revealed for Patients with Protein-Losing Enteropathy
(La Jolla, CA) Researchers at the Burnham Institute for Medical Research (Burnham Institute) have developed the first model to study intestinal protein leakage in mice, allowing the team to control and replicate both genetic deficiencies and environmental damages in an in vivo setting. Protein-losing enteropathy (PLE) encompasses conditions that involve the abnormal leakage of blood proteins into the digestive tract. One type of PLE is observed in children who have undergone Fontan surgery, a procedure used to alleviate certain congenital heart defects. Half of post-Fontan patients who develop PLE die from this condition, due largely to therapeutic options that are inadequate and accompanied by serious side effects.

A study performed by the laboratory of Hudson Freeze, Ph.D., at the Burnham Institute has been published in the Journal of Clinical Investigation (JCI), describing both the science behind PLE and also a way to treat the disease that side steps some of the severe complications of current treatments.

Dr. Freeze’s group, led by Lars Bode, Ph.D., identified commonalities in clinical observations of PLE patients that recognized several key features of PLE pathogenesis; in particular, it is episodic and its onset is often associated with viral infection and a proinflammatory state. The most intriguing commonality that the group observed in PLE patients is the specific loss of heparan sulfate (HS) from intestinal epithelial cells during PLE episodes. Importantly, the study revealed that loss of HS is a key factor in promoting protein leakage and makes the intestine more susceptible to inflammation and increased hypertension. Co-author Simon Murch, M.D., University of Warwick, UK, first noticed the loss of intestinal cell HS in one of their previous collaborations.
“When heparan sulfate is missing, the inflammatory molecules pack a much greater punch and impact than when HS is there on the cell surface,” said Dr. Freeze, who is Professor and Co-Director of the Tumor Microenvironment Program at Burnham Institute.

The group had previously observed that soluble heparin compensates for loss of heparan sulfate and prevents protein leakage in vitro. However, long-term therapy with anticoagulant heparin has severe side effects, including bleeding, thrombocytopenia and osteoporosis. However, the study also revealed an alternative form of heparin as a potential therapy. By adapting well-established clinical assays to assess intestinal protein leakage in mice, Dr. Freeze’s team found that a heparin analog, 2,3-de-O-sulfated heparin, also prevented protein leakage both in vitro and in mice without causing bleeding. This compound exhibits greatly reduced anticoagulant activity, compared to unmodified heparin, which may mean that it can be used safely at much higher doses to treat PLE.

The PLE studies performed by the Freeze laboratory are funded by a gift from the Children’s Hearts Fund (CHF), in association with the Women and Children's Hospital of Buffalo Foundation, whose mission is to fund research on the causes of, and cures for, complications following cardiac surgery in children. Thanks to CHF, Dr. Freeze’s group will continue to work on further understanding the mechanism behind PLE, which may lead to better and safer alternative therapies for this devastating disease.

Dr. Bode received support for these studies from a research grant awarded by the Deutsche Forschungsgemeinschaft in Germany.

About Burnham Institute for Medical Research
Burnham Institute for Medical Research conducts world-class collaborative research dedicated to finding cures for human disease, improving quality of life, and thus creating a legacy for its employees, donors, and community. The Institute is headquartered in La Jolla, CA where it was established as a nonprofit, public benefit corporation in 1976 and is now home to three major centers: a National Cancer Institute-designated Cancer Center; the Del E. Webb Center for Neurosciences, Aging and Stem Cell Research; and the Infectious and Inflammatory Disease Center. In 2006, Burnham established a center for bionanotechnology research at the University of California, Santa Barbara. Burnham is currently establishing a campus at Lake Nona in Orlando, Florida that will focus on diabetes and obesity research and will expand the Institute’s drug discovery capabilities. Today, Burnham employs more than 800 people and ranks consistently among the world’s top 25 organizations for its research impact and among the top four research institutes nationally for NIH grant funding. For additional information about Burnham and to learn about ways to support its research, visit www.burnham.org.
 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
ALL THE NEWS : News1 ; News2 ; News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.